#BEGIN_DRUGCARD DB02482

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C4H10NO6P

# Chemical_IUPAC_Name:
(2R,3S)-2-amino-3-(phosphonooxy)butanoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
The phosphoric acid ester of threonine. Used as an identifier in the analysis of peptides, proteins, and enzymes. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Indicators and Reagents

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Phosphonothreonine

# HET_ID:
TPO

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C4H10NO6P/c1-2(3(5)4(6)7)11-12(8,9)10/h2-3H,5H2,1H3,(H,6,7)(H2,8,9,10)/t2-,3+/m0/s1

# InChI_Key:
InChIKey=USRGIUJOYOXOQJ-STHAYSLISA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2482

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
199.0991

# Molecular_Weight_Mono:
199.024573569

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1FOT

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-1.9

# Predicted_LogS:
-0.93

# Predicted_Water_Solubility:
2.35e+01 g/l

# Primary_Accession_No:
DB02482

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
10976469

# PubChem_Substance_ID:
46506053

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT03092

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
C[C@H](OP(O)(O)=O)[C@@H](N)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:11 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_10_Cellular_Location:
Not Available

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
MAPK1

# Drug_Target_10_GenBank_ID_Gene:
M84489

# Drug_Target_10_GenBank_ID_Protein:
182191

# Drug_Target_10_GeneCard_ID:
MAPK1

# Drug_Target_10_Gene_Name:
MAPK1

# Drug_Target_10_Gene_Sequence:
>1083 bp
ATGGCGGCGGCGGCGGCGGCGGGCGCGGGCCCGGAGATGGTCCGCGGGCAGGTGTTCGAC
GTGGGGCCGCGCTACACCAACCTCTCGTACATCGGCGAGGGCGCCTACGGCATGGTGTGC
TCTGCTTATGATAATGTCAACAAAGTTCGAGTAGCTATCAAGAAAATCAGCCCCTTTGAG
CACCAGACCTACTGCCAGAGAACCCTGAGGGAGATAAAAATCTTACTGCGCTTCAGACAT
GAGAACATCATTGGAATCAATGACATTATTCGAGCACCAACCATCGAGCAAATGAAAGAT
GTATATATAGTACAGGACCTCATGGAAACAGATCTTTACAAGCTCTTGAAGACACAACAC
CTCAGCAATGACCATATCTGCTATTTTCTCTACCAGATCCTCAGAGGGTTAAAATATATC
CATTCAGCTAACGTTCTGCACCGTGACCTCAAGCCTTCCAACCTGCTGCTCAACACCACC
TGTGATCTCAAGATCTGTGACTTTGGCCTGGCCCGTGTTGCAGATCCAGACCATGATCAC
ACAGGGTTCCTGACAGAATATGTGGCCACACGTTGGTACAGGGCTCCAGAAATTATGTTG
AATTCCAAGGGCTACACCAAGTCCATTGATATTTGGTCTGTAGGCTGCATTCTGGCAGAA
ATGCTTTCCAACAGGCCCATCTTTCCAGGGAAGCATTATCTTGACCAGCTGAATCACATT
TTGGGTATTCTTGGATCCCCATCACAAGAAGACCTGAATTGTATAATAAATTTAAAAGCT
AGGAACTATTTGCTTTCTCTTCCACACAAAAATAAGGTGCCATGGAACAGGCTGTTCCCA
AATGCTGACTCCAAAGCTCTGGACTTATTGGACAAAATGTTGACATTCAACCCACACAAG
AGGATTGAAGTAGAACAGGCTCTGGCCCACCCATATCTGGAGCAGTATTACGACCCGAGT
GACGAGCCCATCGCCGAAGCACCATTCAAGTTCGACATGGAATTGGATGACTTGCCTAAG
GAAAAGCTAAAAGAACTAATTTTTGAAGAGACTGCTAGATTCCAGCCAGGATACAGATCT
TAA

# Drug_Target_10_General_Function:
Involved in MAP kinase activity

# Drug_Target_10_General_References:
12665801	Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, Vandekerckhove J: Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9. Epub 2003 Mar 31.
1319925	Gonzalez FA, Raden DL, Rigby MR, Davis RJ: Heterogeneous expression of four MAP kinase isoforms in human tissues. FEBS Lett. 1992 Jun 15;304(2-3):170-8.
1540184	Owaki H, Makar R, Boulton TG, Cobb MH, Geppert TD: Extracellular signal-regulated kinases in T cells: characterization of human ERK1 and ERK2 cDNAs. Biochem Biophys Res Commun. 1992 Feb 14;182(3):1416-22.
8794306	Greenway A, Azad A, Mills J, McPhee D: Human immunodeficiency virus type 1 Nef binds directly to Lck and mitogen-activated protein kinase, inhibiting kinase activity. J Virol. 1996 Oct;70(10):6701-8.

# Drug_Target_10_HGNC_ID:
HGNC:6871

# Drug_Target_10_HPRD_ID:
01496

# Drug_Target_10_ID:
1176

# Drug_Target_10_Locus:
22q11.2|22q11.21

# Drug_Target_10_Molecular_Weight:
41390

# Drug_Target_10_Name:
Mitogen-activated protein kinase 1

# Drug_Target_10_Number_of_Residues:
360

# Drug_Target_10_PDB_ID:
4ERK

# Drug_Target_10_Pathway:
Bevacizumab Pathway	SMP00420
Cetuximab Pathway	SMP00474
Erlotinib Pathway	SMP00472
Gefitinib Pathway	SMP00473
Panitumumab Pathway	SMP00475
Trastuzumab Pathway	SMP00476
Vatalanib Pathway	SMP00421

# Drug_Target_10_Pfam_Domain_Function:
PF00069	Pkinase

# Drug_Target_10_Protein_Sequence:
>Mitogen-activated protein kinase 1
MAAAAAAGAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNVNKVRVAIKKISPFE
HQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQH
LSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDH
TGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHI
LGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHK
RIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRS

# Drug_Target_10_Reaction:
ATP + a protein = ADP + a phosphoprotein

# Drug_Target_10_Signals:
None

# Drug_Target_10_Specific_Function:
Involved in both the initiation and regulation of meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating a number of transcription factors such as ELK1. Phosphorylates EIF4EBP1; required for initiation of translation. Phosphorylates microtubule-associated protein 2 (MAP2). Phosphorylates SPZ1

# Drug_Target_10_SwissProt_ID:
P28482

# Drug_Target_10_SwissProt_Name:
MK01_HUMAN

# Drug_Target_10_Synonyms:
EC 2.7.11.24
ERK-2
ERT1
Extracellular signal-regulated kinase 2
MAP kinase 2
MAPK 2
Mitogen-activated protein kinase 2
p42-MAPK

# Drug_Target_10_Theoretical_pI:
6.99

# Drug_Target_10_Transmembrane_Regions:
None

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
RHO

# Drug_Target_1_GenBank_ID_Gene:
U49742

# Drug_Target_1_GenBank_ID_Protein:
1236137

# Drug_Target_1_GeneCard_ID:
RHO

# Drug_Target_1_Gene_Name:
RHO

# Drug_Target_1_Gene_Sequence:
>1047 bp
ATGAATGGCACAGAAGGCCCTAACTTCTACGTGCCCTTCTCCAATGCGACGGGTGTGGTA
CGCAGCCCCTTCGAGTACCCACAGTACTACCTGGCTGAGCCATGGCAGTTCTCCATGCTG
GCCGCCTACATGTTTCTGCTGATCGTGCTGGGCTTCCCCATCAACTTCCTCACGCTCTAC
GTCACCGTCCAGCACAAGAAGCTGCGCACGCCTCTCAACTACATCCTGCTCAACCTAGCC
GTGGCTGACCTCTTCATGGTCCTAGGTGGCTTCACCAGCACCCTCTACACCTCTCTGCAT
GGATACTTCGTCTTCGGGCCCACAGGATGCAATTTGGAGGGCTTCTTTGCCACCCTGGGC
GGTGAAATTGCCCTGTGGTCCTTGGTGGTCCTGGCCATCGAGCGGTACGTGGTGGTGTGT
AAGCCCATGAGCAACTTCCGCTTCGGGGAGAACCATGCCATCATGGGCGTTGCCTTCACC
TGGGTCATGGCGCTGGCCTGCGCCGCACCCCCACTCGCCGGCTGGTCCAGGTACATCCCC
GAGGGCCTGCAGTGCTCGTGTGGAATCGACTACTACACGCTCAAGCCGGAGGTCAACAAC
GAGTCTTTTGTCATCTACATGTTCGTGGTCCACTTCACCATCCCCATGATTATCATCTTT
TTCTGCTATGGGCAGCTCGTCTTCACCGTCAAGGAGGCCGCTGCCCAGCAGCAGGAGTCA
GCCACCACACAGAAGGCAGAGAAGGAGGTCACCCGCATGGTCATCATCATGGTCATCGCT
TTCCTGATCTGCTGGGTGCCCTACGCCAGCGTGGCATTCTACATCTTCACCCACCAGGGC
TCCAACTTCGGTCCCATCTTCATGACCATCCCAGCGTTCTTTGCCAAGAGCGCCGCCATC
TACAACCCTGTCATCTATATCATGATGAACAAGCAGTTCCGGAACTGCATGCTCACCACC
ATCTGCTGCGGCAAGAACCCACTGGGTGACGATGAGGCCTCTGCTACCGTGTCCAAGACG
GAGACGAGCCAGGTGGCCCCGGCCTAA

# Drug_Target_1_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_1_General_References:
1302614	Farrar GJ, Findlay JB, Kumar-Singh R, Kenna P, Humphries MM, Sharpe E, Humphries P: Autosomal dominant retinitis pigmentosa: a novel mutation in the rhodopsin gene in the original 3q linked family. Hum Mol Genet. 1992 Dec;1(9):769-71.
1391967	Fujiki K, Hotta Y, Hayakawa M, Sakuma H, Shiono T, Noro M, Sakuma T, Tamai M, Hikiji K, Kawaguchi R, et al.: Point mutations of rhodopsin gene found in Japanese families with autosomal dominant retinitis pigmentosa (ADRP). Jpn J Hum Genet. 1992 Jun;37(2):125-32.
1833777	Dryja TP, Hahn LB, Cowley GS, McGee TL, Berson EL: Mutation spectrum of the rhodopsin gene among patients with autosomal dominant retinitis pigmentosa. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9370-4.
1840561	Gal A, Artlich A, Ludwig M, Niemeyer G, Olek K, Schwinger E, Schinzel A: Pro-347-Arg mutation of the rhodopsin gene in autosomal dominant retinitis pigmentosa. Genomics. 1991 Oct;11(2):468-70.
1862076	Sung CH, Davenport CM, Hennessey JC, Maumenee IH, Jacobson SG, Heckenlively JR, Nowakowski R, Fishman G, Gouras P, Nathans J: Rhodopsin mutations in autosomal dominant retinitis pigmentosa. Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6481-5.
1897520	Sheffield VC, Fishman GA, Beck JS, Kimura AE, Stone EM: Identification of novel rhodopsin mutations associated with retinitis pigmentosa by GC-clamped denaturing gradient gel electrophoresis. Am J Hum Genet. 1991 Oct;49(4):699-706.
1985460	Inglehearn CF, Bashir R, Lester DH, Jay M, Bird AC, Bhattacharya SS: A 3-bp deletion in the rhodopsin gene in a family with autosomal dominant retinitis pigmentosa. Am J Hum Genet. 1991 Jan;48(1):26-30.
2137202	Dryja TP, McGee TL, Reichel E, Hahn LB, Cowley GS, Yandell DW, Sandberg MA, Berson EL: A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. Nature. 1990 Jan 25;343(6256):364-6.
2215617	Dryja TP, McGee TL, Hahn LB, Cowley GS, Olsson JE, Reichel E, Sandberg MA, Berson EL: Mutations within the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa. N Engl J Med. 1990 Nov 8;323(19):1302-7.
2239971	Farrar GJ, Kenna P, Redmond R, McWilliam P, Bradley DG, Humphries MM, Sharp EM, Inglehearn CF, Bashir R, Jay M, et al.: Autosomal dominant retinitis pigmentosa: absence of the rhodopsin proline----histidine substitution (codon 23) in pedigrees from Europe. Am J Hum Genet. 1990 Dec;47(6):941-5.
6589631	Nathans J, Hogness DS: Isolation and nucleotide sequence of the gene encoding human rhodopsin. Proc Natl Acad Sci U S A. 1984 Aug;81(15):4851-5.
7633434	Macke JP, Hennessey JC, Nathans J: Rhodopsin mutation proline347-to-alanine in a family with autosomal dominant retinitis pigmentosa indicates an important role for proline at position 347. Hum Mol Genet. 1995 Apr;4(4):775-6.
7846071	Sieving PA, Richards JE, Naarendorp F, Bingham EL, Scott K, Alpern M: Dark-light: model for nightblindness from the human rhodopsin Gly-90-->Asp mutation. Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):880-4.
7981701	Fuchs S, Kranich H, Denton MJ, Zrenner E, Bhattacharya SS, Humphries P, Gal A: Three novel rhodopsin mutations (C110F, L131P, A164V) in patients with autosomal dominant retinitis pigmentosa. Hum Mol Genet. 1994 Jul;3(7):1203.
7987326	Antinolo G, Sanchez B, Borrego S, Rueda T, Chaparro P, Cabeza JC: Identification of a new mutation at codon 171 of rhodopsin gene causing autosomal dominant retinitis pigmentosa. Hum Mol Genet. 1994 Aug;3(8):1421.
7987331	Souied E, Gerber S, Rozet JM, Bonneau D, Dufier JL, Ghazi I, Philip N, Soubrane G, Coscas G, Munnich A, et al.: Five novel missense mutations of the rhodopsin gene in autosomal dominant retinitis pigmentosa. Hum Mol Genet. 1994 Aug;3(8):1433-4.
7987385	Kumaramanickavel G, Maw M, Denton MJ, John S, Srikumari CR, Orth U, Oehlmann R, Gal A: Missense rhodopsin mutation in a family with recessive RP. Nat Genet. 1994 Sep;8(1):10-1.
8045708	Rosas DJ, Roman AJ, Weissbrod P, Macke JP, Nathans J: Autosomal dominant retinitis pigmentosa in a large family: a clinical and molecular genetic study. Invest Ophthalmol Vis Sci. 1994 Jul;35(8):3134-44.
8076945	Reig C, Antich J, Gean E, Garcia-Sandoval B, Ramos C, Ayuso C, Carballo M: Identification of a novel rhodopsin mutation (Met-44-Thr) in a simplex case of retinitis pigmentosa. Hum Genet. 1994 Sep;94(3):283-6.
8081400	al-Maghtheh M, Inglehearn C, Lunt P, Jay M, Bird A, Bhattacharya S: Two new rhodopsin transversion mutations (L40R; M216K) in families with autosomal dominant retinitis pigmentosa. Hum Mutat. 1994;3(4):409-10.
8088850	Vaithinathan R, Berson EL, Dryja TP: Further screening of the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa. Genomics. 1994 May 15;21(2):461-3.
8317502	Macke JP, Davenport CM, Jacobson SG, Hennessey JC, Gonzalez-Fernandez F, Conway BP, Heckenlively J, Palmer R, Maumenee IH, Sieving P, et al.: Identification of novel rhodopsin mutations responsible for retinitis pigmentosa: implications for the structure and function of rhodopsin. Am J Hum Genet. 1993 Jul;53(1):80-9.
8353500	Kranich H, Bartkowski S, Denton MJ, Krey S, Dickinson P, Duvigneau C, Gal A: Autosomal dominant 'sector' retinitis pigmentosa due to a point mutation predicting an Asn-15-Ser substitution of rhodopsin. Hum Mol Genet. 1993 Jun;2(6):813-4.
8358437	Dryja TP, Berson EL, Rao VR, Oprian DD: Heterozygous missense mutation in the rhodopsin gene as a cause of congenital stationary night blindness. Nat Genet. 1993 Jul;4(3):280-3.
8401533	al-Maghtheh M, Gregory C, Inglehearn C, Hardcastle A, Bhattacharya S: Rhodopsin mutations in autosomal dominant retinitis pigmentosa. Hum Mutat. 1993;2(4):249-55.
8554077	Souied E, Soubrane G, Benlian P, Coscas GJ, Gerber S, Munnich A, Kaplan J: Retinitis punctata albescens associated with the Arg135Trp mutation in the rhodopsin gene. Am J Ophthalmol. 1996 Jan;121(1):19-25.
9452035	Goliath R, Bardien S, September A, Martin R, Ramesar R, Greenberg J: Rhodopsin mutation G109R in a family with autosomal dominant retinitis pigmentosa. Hum Mutat. 1998;Suppl 1:S40-1.
9888392	al-Jandal N, Farrar GJ, Kiang AS, Humphries MM, Bannon N, Findlay JB, Humphries P, Kenna PF: A novel mutation within the rhodopsin gene (Thr-94-Ile) causing autosomal dominant congenital stationary night blindness. Hum Mutat. 1999;13(1):75-81.

# Drug_Target_1_HGNC_ID:
HGNC:10012

# Drug_Target_1_HPRD_ID:
01584

# Drug_Target_1_ID:
2207

# Drug_Target_1_Locus:
3q21-q24

# Drug_Target_1_Molecular_Weight:
38893

# Drug_Target_1_Name:
Rhodopsin

# Drug_Target_1_Number_of_Residues:
348

# Drug_Target_1_PDB_ID:
1LN6

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_1_Protein_Sequence:
>Rhodopsin
MNGTEGPNFYVPFSNATGVVRSPFEYPQYYLAEPWQFSMLAAYMFLLIVLGFPINFLTLY
VTVQHKKLRTPLNYILLNLAVADLFMVLGGFTSTLYTSLHGYFVFGPTGCNLEGFFATLG
GEIALWSLVVLAIERYVVVCKPMSNFRFGENHAIMGVAFTWVMALACAAPPLAGWSRYIP
EGLQCSCGIDYYTLKPEVNNESFVIYMFVVHFTIPMIIIFFCYGQLVFTVKEAAAQQQES
ATTQKAEKEVTRMVIIMVIAFLICWVPYASVAFYIFTHQGSNFGPIFMTIPAFFAKSAAI
YNPVIYIMMNKQFRNCMLTTICCGKNPLGDDEASATVSKTETSQVAPA

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Visual pigments are the light-absorbing molecules that mediate vision. They consist of an apoprotein, opsin, covalently linked to cis-retinal

# Drug_Target_1_SwissProt_ID:
P08100

# Drug_Target_1_SwissProt_Name:
OPSD_HUMAN

# Drug_Target_1_Synonyms:
Opsin-2

# Drug_Target_1_Theoretical_pI:
6.64

# Drug_Target_1_Transmembrane_Regions:
37-61
74-98
114-133
153-176
203-230
253-276
285-309

# Drug_Target_2_Cellular_Location:
Cytoplasm (By similarity). Nucleus (By similarity)

# Drug_Target_2_Chromosome_Location:
1

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
X07767

# Drug_Target_2_GenBank_ID_Protein:
35479

# Drug_Target_2_GeneCard_ID:
PRKACA

# Drug_Target_2_Gene_Name:
PRKACA

# Drug_Target_2_Gene_Sequence:
>1056 bp
ATGGGCAACGCCGCCGCCGCCAAGAAGGGCAGCGAGCAGGAGAGCGTGAAAGAATTCTTA
GCCAAAGCCAAAGAAGATTTTCTTAAAAAATGGGAAAGTCCCGCTCAGAACACAGCCCAC
TTGGATCAGTTTGAACGAATCAAGACCCTCGGCACGGGCTCCTTCGGGCGGGTGATGCTG
GTGAAACACAAGGAGACCGGGAACCACTATGCCATGAAGATCCTCGACAAACAGAAGGTG
GTGAAACTGAAACAGATCGAACACACCCTGAATGAAAAGCGCATCCTGCAAGCTGTCAAC
TTTCCGTTCCTCGTCAAACTCGAGTTCTCCTTCAAGGACAACTCAAACTTATACATGGTC
ATGGAGTACGTGCCCGGCGGGGAGATGTTCTCACACCTACGGCGGATCGGAAGGTTCAGT
GAGCCCCATGCCCGTTTCTACGCGGCCCAGATCGTCCTGACCTTTGAGTATCTGCACTCG
CTGGATCTCATCTACAGGGACCTGAAGCCGGAGAATCTGCTCATTGACCAGCAGGGCTAC
ATTCAGGTGACAGACTTCGGTTTCGCCAAGCGCGTGAAGGGCCGCACTTGGACCTTGTGC
GGCACCCCTGAGTACCTGGCCCCTGAGATTATCCTGAGCAAAGGCTACAACAAGGCCGTG
GACTGGTGGGCCCTGGGGGTTCTTATCTATGAAATGGCCGCTGGCTACCCGCCCTTCTTC
GCAGACCAGCCCATCCAGATCTATGAGAAGATCGTCTCTGGGAAGGTGCGCTTCCCTTCC
CACTTCAGCTCTGACTTGAAGGACCTGCTGCGGAACCTCCTGCAGGTAGATCTCACCAAG
CGCTTTGGGAACCTCAAGAATGGGGTCAACGATATCAAGAACCACAAGTGGTTTGCCACA
ACTGACTGGATTGCCATCTACCAGAGGAAGGTGGAAGCTCCCTTCATACCAAAGTTTAAA
GGCCCTGGGGATACGAGTAACTTTGACGACTATGAGGAAGAAGAAATCCGGGTCTCCATC
AATGAGAAGTGTGGCAAGGAGTTTTCTGAGTTTTAG

# Drug_Target_2_General_Function:
Involved in ATP binding

# Drug_Target_2_General_References:
10841548	Desseyn JL, Burton KA, McKnight GS: Expression of a nonmyristylated variant of the catalytic subunit of protein kinase A during male germ-cell development. Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6433-8.
10982398	Agustin JT, Wilkerson CG, Witman GB: The unique catalytic subunit of sperm cAMP-dependent protein kinase is the product of an alternative Calpha mRNA expressed specifically in spermatogenic cells. Mol Biol Cell. 2000 Sep;11(9):3031-44.
12509440	Ficarro S, Chertihin O, Westbrook VA, White F, Jayes F, Kalab P, Marto JA, Shabanowitz J, Herr JC, Hunt DF, Visconti PE: Phosphoproteome analysis of capacitated human sperm. Evidence of tyrosine phosphorylation of a kinase-anchoring protein 3 and valosin-containing protein/p97 during capacitation. J Biol Chem. 2003 Mar 28;278(13):11579-89. Epub 2002 Dec 30.
14702039	Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
17081983	Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, Mann M: Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell. 2006 Nov 3;127(3):635-48.
2843813	Maldonado F, Hanks SK: A cDNA clone encoding human cAMP-dependent protein kinase catalytic subunit C alpha. Nucleic Acids Res. 1988 Aug 25;16(16):8189-90.

# Drug_Target_2_HGNC_ID:
GNC:9380

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
6263

# Drug_Target_2_Locus:
19p13.1

# Drug_Target_2_Molecular_Weight:
40589.4

# Drug_Target_2_Name:
cAMP-dependent protein kinase catalytic subunit alpha

# Drug_Target_2_Number_of_Residues:
351

# Drug_Target_2_PDB_ID:
1CTP

# Drug_Target_2_Pathway:
Acebutolol Pathway	SMP00296
Alprenolol Pathway	SMP00297
Atenolol Pathway	SMP00298
Betaxolol Pathway	SMP00299
Bisoprolol Pathway	SMP00300
Carvedilol Pathway	SMP00367
Celecoxib Pathway	SMP00096
Citalopram Pathway	SMP00424
Desipramine Pathway	SMP00423
Escitalopram Pathway	SMP00425
Esmolol Pathway	SMP00301
Etodolac Pathway	SMP00084
Fluoxetine Pathway	SMP00426
Imipramine Pathway	SMP00422
Labetalol Pathway	SMP00368
Meloxicam Pathway	SMP00106
Metoprolol Pathway	SMP00302
Nadolol Pathway	SMP00303
Nebivolol Pathway	SMP00366
Oxprenolol Pathway	SMP00304
Penbutolol Pathway	SMP00305
Pindolol Pathway	SMP00306
Propranolol Pathway	SMP00307
Rofecoxib Pathway	SMP00087
Valdecoxib Pathway	SMP00116

# Drug_Target_2_Pfam_Domain_Function:
PF00069	Pkinase

# Drug_Target_2_Protein_Sequence:
>cAMP-dependent protein kinase catalytic subunit alpha
MGNAAAAKKGSEQESVKEFLAKAKEDFLKKWESPAQNTAHLDQFERIKTLGTGSFGRVML
VKHKETGNHYAMKILDKQKVVKLKQIEHTLNEKRILQAVNFPFLVKLEFSFKDNSNLYMV
MEYVPGGEMFSHLRRIGRFSEPHARFYAAQIVLTFEYLHSLDLIYRDLKPENLLIDQQGY
IQVTDFGFAKRVKGRTWTLCGTPEYLAPEIILSKGYNKAVDWWALGVLIYEMAAGYPPFF
ADQPIQIYEKIVSGKVRFPSHFSSDLKDLLRNLLQVDLTKRFGNLKNGVNDIKNHKWFAT
TDWIAIYQRKVEAPFIPKFKGPGDTSNFDDYEEEEIRVSINEKCGKEFSEF

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Phosphorylates a large number of substrates in the cytoplasm and the nucleus

# Drug_Target_2_SwissProt_ID:
P17612

# Drug_Target_2_SwissProt_Name:
KAPCA_HUMAN

# Drug_Target_2_Synonyms:
PKA C-alpha

# Drug_Target_2_Theoretical_pI:
9.22

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
Not Available

# Drug_Target_3_GenBank_ID_Protein:
Not Available

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
PRKACB

# Drug_Target_3_Gene_Sequence:
Not Available

# Drug_Target_3_General_Function:
Not Available

# Drug_Target_3_General_References:
Not Available

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
6985

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
Not Available

# Drug_Target_3_Name:
cAMP-dependent protein kinase catalytic subunit beta

# Drug_Target_3_Number_of_Residues:
0

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Celecoxib Pathway	SMP00096
Etodolac Pathway	SMP00084
Meloxicam Pathway	SMP00106
Rofecoxib Pathway	SMP00087
Valdecoxib Pathway	SMP00116

# Drug_Target_3_Pfam_Domain_Function:
Not Available

# Drug_Target_3_Protein_Sequence:
Not Available

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
Not Available

# Drug_Target_3_Specific_Function:
Not Available

# Drug_Target_3_SwissProt_ID:
P22694

# Drug_Target_3_SwissProt_Name:
KAPCB_HUMAN

# Drug_Target_3_Synonyms:
Not Available

# Drug_Target_3_Theoretical_pI:
Not Available

# Drug_Target_3_Transmembrane_Regions:
Not Available

# Drug_Target_4_Cellular_Location:
Nucleus

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
CDK7

# Drug_Target_4_GenBank_ID_Gene:
X79193

# Drug_Target_4_GenBank_ID_Protein:
485909

# Drug_Target_4_GeneCard_ID:
CDK7

# Drug_Target_4_Gene_Name:
CDK7

# Drug_Target_4_Gene_Sequence:
>1041 bp
ATGGCTCTGGACGTGAAGTCTCGGGCAAAGCGTTATGAGAAGCTGGACTTCCTTGGGGAG
GGACAGTTTGCCACCGTTTACAAGGCCAGAGATAAGAATACCAACCAAATTGTCGCCATT
AAGAAAATCAAACTTGGACATAGATCAGAAGCTAAAGATGGTATAAATAGAACCGCCTTA
AGAGAGATAAAATTATTACAGGAGCTAAGTCATCCAAATATAATTGGTCTCCTTGATGCT
TTTGGACATAAATCTAATATTAGCCTTGTCTTTGATTTTATGGAAACTGATCTAGAGGTT
ATAATAAAGGATAATAGTCTTGTGCTGACACCATCACACATCAAAGCCTACATGTTGATG
ACTCTTCAAGGATTAGAATATTTACATCAACATTGGATCCTACATAGGGATCTGAAACCA
AACAACTTGTTGCTAGATGAAAATGGAGTTCTAAAACTGGCAGATTTTGGCCTGGCCAAA
TCTTTTGGGAGCCCCAATAGAGCTTATACACATCAGGTTGTAACCAGGTGGTATCGGGCC
CCCGAGTTACTATTTGGAGCTAGGATGTATGGTGTAGGTGTGGACATGTGGGCTGTTGGC
TGTATATTAGCAGAGTTACTTCTAAGGGTTCCTTTTTTGCCAGGAGATTCAGACCTTGAT
CAGCTAACAAGAATATTTGAAACTTTGGGCACACCAACTGAGGAACAGTGGCCGGACATG
TGTAGTCTTCCAGATTATGTGACATTTAAGAGTTTCCCTGGAATACCTTTGCATCACATC
TTCAGTGCAGCAGGAGACGACTTACTAGATCTCATACAAGGCTTATTCTTATTTAATCCA
TGTGCTCGAATTACGGCCACACAGGCACTGAAAATGAAGTATTTCAGTAATCGGCCAGGG
CCAACACCTGGATGTCAGCTGCCAAGACCAAACTGTCCAGTGGAAACCTTAAAGGAGCAA
TCAAATCCAGCTTTGGCAATAAAAAGGAAAAGAACAGAGGCCTTAGAACAAGGAGGATTG
CCCAAGAAACTAATTTTTTAA

# Drug_Target_4_General_Function:
Involved in protein kinase activity

# Drug_Target_4_General_References:
10024882	Tirode F, Busso D, Coin F, Egly JM: Reconstitution of the transcription factor TFIIH: assignment of functions for the three enzymatic subunits, XPB, XPD, and cdk7. Mol Cell. 1999 Jan;3(1):87-95.
7929589	Tassan JP, Schultz SJ, Bartek J, Nigg EA: Cell cycle analysis of the activity, subcellular localization, and subunit composition of human CAK (CDK-activating kinase). J Cell Biol. 1994 Oct;127(2):467-78.
7936635	Darbon JM, Devault A, Taviaux S, Fesquet D, Martinez AM, Galas S, Cavadore JC, Doree M, Blanchard JM: Cloning, expression and subcellular localization of the human homolog of p40MO15 catalytic subunit of cdk-activating kinase. Oncogene. 1994 Nov;9(11):3127-38.
8069918	Fisher RP, Morgan DO: A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell. 1994 Aug 26;78(4):713-24.
8208544	Levedakou EN, He M, Baptist EW, Craven RJ, Cance WG, Welcsh PL, Simmons A, Naylor SL, Leach RJ, Lewis TB, et al.: Two novel human serine/threonine kinases with homologies to the cell cycle regulating Xenopus MO15, and NIMA kinases: cloning and characterization of their expression pattern. Oncogene. 1994 Jul;9(7):1977-88.
8208556	Wu L, Yee A, Liu L, Carbonaro-Hall D, Venkatesan N, Tolo VT, Hall FL: Molecular cloning of the human CAK1 gene encoding a cyclin-dependent kinase-activating kinase. Oncogene. 1994 Jul;9(7):2089-96.
9832506	Akoulitchev S, Reinberg D: The molecular mechanism of mitotic inhibition of TFIIH is mediated by phosphorylation of CDK7. Genes Dev. 1998 Nov 15;12(22):3541-50.

# Drug_Target_4_HGNC_ID:
HGNC:1778

# Drug_Target_4_HPRD_ID:
15993

# Drug_Target_4_ID:
3482

# Drug_Target_4_Locus:
5q12.1

# Drug_Target_4_Molecular_Weight:
39039

# Drug_Target_4_Name:
Cell division protein kinase 7

# Drug_Target_4_Number_of_Residues:
346

# Drug_Target_4_PDB_ID:
1UA2

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00069	Pkinase

# Drug_Target_4_Protein_Sequence:
>Cell division protein kinase 7
MALDVKSRAKRYEKLDFLGEGQFATVYKARDKNTNQIVAIKKIKLGHRSEAKDGINRTAL
REIKLLQELSHPNIIGLLDAFGHKSNISLVFDFMETDLEVIIKDNSLVLTPSHIKAYMLM
TLQGLEYLHQHWILHRDLKPNNLLLDENGVLKLADFGLAKSFGSPNRAYTHQVVTRWYRA
PELLFGARMYGVGVDMWAVGCILAELLLRVPFLPGDSDLDQLTRIFETLGTPTEEQWPDM
CSLPDYVTFKSFPGIPLHHIFSAAGDDLLDLIQGLFLFNPCARITATQALKMKYFSNRPG
PTPGCQLPRPNCPVETLKEQSNPALAIKRKRTEALEQGGLPKKLIF

# Drug_Target_4_Reaction:
ATP + a protein = ADP + a phosphoprotein

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Cyclin-dependent kinases (CDKs) are activated by the binding to a cyclin and mediate the progression through the cell cycle. Each different complex controls a specific transition between two subsequent phases in the cell cycle. CDK7 is the catalytic subunit of the CDK-activating kinase (CAK) complex, a serine-threonine kinase. CAK activates the cyclin-associated kinases CDC2/CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation. CAK complexed to the core-TFIIH basal transcription factor activates RNA polymerase II by serine phosphorylation of the repetitive C-terminus domain (CTD) of its large subunit (POLR2A), allowing its escape from the promoter and elongation of the transcripts. Involved in cell cycle control and in RNA transcription by RNA polymerase II. Its expression and activity are constant throughout the cell cycle

# Drug_Target_4_SwissProt_ID:
P50613

# Drug_Target_4_SwissProt_Name:
CDK7_HUMAN

# Drug_Target_4_Synonyms:
39 kDa protein kinase
CAK
CAK1
CDK- activating kinase
EC 2.7.11.22
EC 2.7.11.23
P39 Mo15
STK1
TFIIH basal transcription factor complex kinase subunit

# Drug_Target_4_Theoretical_pI:
8.68

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Not Available

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
U90625

# Drug_Target_5_GenBank_ID_Protein:
1895094

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
cobD

# Drug_Target_5_Gene_Sequence:
>1095 bp
ATGGCTTTATTCAACACCGCGCATGGCGGTAATATTCGGGAACCCGCAACGGTGTTGGGC
ATCTCCCCTGACCATTTACTGGATTTTACCGCAAACATTAATCCGCTGGGTATGCCTGTC
AGCTTGAAACCCCCCCTTATCGACAATCTGGACTGCATTGAGCGCTACCCGGACGCCGAT
TATTTTCATTTGCACCAGGCGCTGGCGCGTCATCATCAGGTGCCGGCATCGTGGATACTG
GCGGGAAATGGCGAGACGGAGTCAATCTTTACCGTGGCGAGCGGTCTTAAACCGCGTCGT
GCAATGATTGTCACGCCAGGTTTCGCGGAGTATGGCCGGGCGCTGGCGCAAAGTGGCTGT
GAAATTCGTCGCTGGTCTCTACGCGAAGCGGATGGCTGGCAGCTTACCGATGCCATTCTT
GAGGCGTTGACGCCCGATCTGGACTGCCTGTTTCTGTGTACGCCTAATAATCCTACCGGC
CTGCTGCCGGAGCGGCCGTTATTACAGGCCATTGCCGATCGCTGCAAATCGCTGAACATT
AACCTGATCCTGGATGAAGCGTTTATCGATTTTATTCCGCATGAGACGGGCTTTATTCCT
GCTCTTAAAGATAATCCGCATATCTGGGTGCTGCGTTCGCTGACCAAATTTTATGCCATT
CCCGGCCTGCGGTTGGGATATCTCGTCAATAGCGATGACGCGGCGATGGCGCGGATGCGT
CGCCAACAAATGCCGTGGTCGGTTAACGCGCTGGCGGCGCTTGCCGGTGAGGTAGCGTTA
CAGGATAGCGCCTGGCAACAGGCGACCTGGCATTGGTTACGGGAGGAGGGCGCCCGGTTT
TATCAGGCGCTTTGTCAGCTCCCCCTGCTGACGGTTTATCCCGGGCGGGCAAACTATCTG
TTGTTACGCTGTGAGCGAGAGGATATTGATCTGCAGCGACGGTTGCTGACGCAGCGGATT
TTAATCCGTAGCTGCGCTAACTACCCGGGGCTGGACAGCCGCTATTATCGTGTGGCGATA
CGCAGCGCTGCGCAAAACGAGCGTCTGCTGGCGGCGCTGCGCAATGTGCTTACCGGTATA
GCCCCTGCTGATTGA

# Drug_Target_5_General_Function:
Amino acid transport and metabolism

# Drug_Target_5_General_References:
11677609	McClelland M, Sanderson KE, Spieth J, Clifton SW, Latreille P, Courtney L, Porwollik S, Ali J, Dante M, Du F, Hou S, Layman D, Leonard S, Nguyen C, Scott K, Holmes A, Grewal N, Mulvaney E, Ryan E, Sun H, Florea L, Miller W, Stoneking T, Nhan M, Waterston R, Wilson RK: Complete genome sequence of Salmonella enterica serovar Typhimurium LT2. Nature. 2001 Oct 25;413(6858):852-6.
11939774	Cheong CG, Bauer CB, Brushaber KR, Escalante-Semerena JC, Rayment I: Three-dimensional structure of the L-threonine-O-3-phosphate decarboxylase (CobD) enzyme from Salmonella enterica. Biochemistry. 2002 Apr 16;41(15):4798-808.
12119022	Cheong CG, Escalante-Semerena JC, Rayment I: Structural studies of the L-threonine-O-3-phosphate decarboxylase (CobD) enzyme from Salmonella enterica: the apo, substrate, and product-aldimine complexes. Biochemistry. 2002 Jul 23;41(29):9079-89.
9446573	Brushaber KR, O'Toole GA, Escalante-Semerena JC: CobD, a novel enzyme with L-threonine-O-3-phosphate decarboxylase activity, is responsible for the synthesis of (R)-1-amino-2-propanol O-2-phosphate, a proposed new intermediate in cobalamin biosynthesis in Salmonella typhimurium LT2. J Biol Chem. 1998 Jan 30;273(5):2684-91.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
3005

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
40766

# Drug_Target_5_Name:
Threonine-phosphate decarboxylase

# Drug_Target_5_Number_of_Residues:
364

# Drug_Target_5_PDB_ID:
1LC8

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00155	Aminotran_1_2

# Drug_Target_5_Protein_Sequence:
>Threonine-phosphate decarboxylase
MALFNSAHGGNIREAATVLGISPDQLLDFSANINPLGMPVSVKRALIDNLDCIERYPDAD
YFHLHQALARHHQVPASWILAGNGETESIFTVASGLKPRRAMIVTPGFAEYGRALAQSGC
EIRRWSLREADGWQLTDAILEALTPDLDCLFLCTPNNPTGLLPERPLLQAIADRCKSLNI
NLILDEAFIDFIPHETGFIPALKDNPHIWVLRSLTKFYAIPGLRLGYLVNSDDAAMARMR
RQQMPWSVNALAALAGEVALQDSAWQQATWHWLREEGARFYQALCQLPLLTVYPGRANYL
LLRCEREDIDLQRRLLTQRILIRSCANYPGLDSRYYRVAIRSAAQNERLLAALRNVLTGI
APAD

# Drug_Target_5_Reaction:
L-threonine O-3-phosphate = (R)-1-aminopropan-2-yl phosphate + CO2

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Decarboxylates L-threonine-O-3-phosphate to yield (R)-1- amino-2-propanol O-2-phosphate, the precursor for the linkage between the nucleotide loop and the corrin ring in cobalamin

# Drug_Target_5_SwissProt_ID:
P97084

# Drug_Target_5_SwissProt_Name:
COBD_SALTY

# Drug_Target_5_Synonyms:
EC 4.1.1.81
L-threonine-O-3- phosphate decarboxylase

# Drug_Target_5_Theoretical_pI:
6.92

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Not Available

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
Not Available

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
S100A11

# Drug_Target_6_GenBank_ID_Gene:
D38583

# Drug_Target_6_GenBank_ID_Protein:
Not Available

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
S100A11

# Drug_Target_6_Gene_Sequence:
>318 bp
ATGGCAAAAATCTCCAGCCCTACAGAGACTGAGCGGTGCATCGAGTCCCTGATTGCTGTC
TTCCAGAAGTATGCTGGAAAGGATGGTTATAACTACACTCTCTCCAAGACAGAGTTCCTA
AGCTTCATGAATACAGAACTAGCTGCCTTCACAAAGAACCAGAAGGACCCTGGTGTCCTT
GACCGCATGATGAAGAAACTGGACACCAACAGTGATGGTCAGCTAGATTTCTCAGAATTT
CTTAATCTGATTGGTGGCCTAGCTATGGCTTGCCATGACTCCTTCCTCAAGGCTGTCCCT
TCCCAGAAGCGGACCTGA

# Drug_Target_6_General_Function:
Involved in calcium ion binding

# Drug_Target_6_General_References:
1286667	Rasmussen HH, van Damme J, Puype M, Gesser B, Celis JE, Vandekerckhove J: Microsequences of 145 proteins recorded in the two-dimensional gel protein database of normal human epidermal keratinocytes. Electrophoresis. 1992 Dec;13(12):960-9.
7490069	Tomasetto C, Regnier C, Moog-Lutz C, Mattei MG, Chenard MP, Lidereau R, Basset P, Rio MC: Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-q21.3 region of chromosome 17. Genomics. 1995 Aug 10;28(3):367-76.
7889529	Tanaka M, Adzuma K, Iwami M, Yoshimoto K, Monden Y, Itakura M: Human calgizzarin; one colorectal cancer-related gene selected by a large scale random cDNA sequencing and northern blot analysis. Cancer Lett. 1995 Mar 2;89(2):195-200.

# Drug_Target_6_HGNC_ID:
HGNC:10488

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
4750

# Drug_Target_6_Locus:
1q21

# Drug_Target_6_Molecular_Weight:
11741

# Drug_Target_6_Name:
Protein S100-A11

# Drug_Target_6_Number_of_Residues:
105

# Drug_Target_6_PDB_ID:
Not Available

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00036	efhand
PF01023	S_100

# Drug_Target_6_Protein_Sequence:
>Protein S100-A11
MAKISSPTETERCIESLIAVFQKYAGKDGYNYTLSKTEFLSFMNTELAAFTKNQKDPGVL
DRMMKKLDTNSDGQLDFSEFLNLIGGLAMACHDSFLKAVPSQKRT

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Not Available

# Drug_Target_6_SwissProt_ID:
P31949

# Drug_Target_6_SwissProt_Name:
S10AB_HUMAN

# Drug_Target_6_Synonyms:
Calgizzarin
MLN 70
Protein S100C
S100 calcium-binding protein A11

# Drug_Target_6_Theoretical_pI:
7.26

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Cytoplasm. Mitochondrion

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
Not Available

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
MAPK12

# Drug_Target_7_GenBank_ID_Gene:
X79483

# Drug_Target_7_GenBank_ID_Protein:
Not Available

# Drug_Target_7_GeneCard_ID:
Not Available

# Drug_Target_7_Gene_Name:
MAPK12

# Drug_Target_7_Gene_Sequence:
>1104 bp
ATGAGCTCTCCGCCGCCCACCCGCAGTGGCTTTTACCGCCAGGAGGTGACCAAGACGGCC
TGGGAGGTGCGCGCCGTGTACCGGGACCTGCAGCCCGTGGGCTCGGGCGCCTACGGCGCG
GTGTGCTCGGCCGTGGACGGCCGCACCGGCGCTAAGGTTGCCATCAAGAAGCTGTATCGG
CCCTTCCAGTCCGAGCTGTTCGCCAAGCTCGCCTACCGCGAGCTGCGCCTGCTCAAGCAC
ATGCGCCACGAGAACGTGATCGGGCTGCTGGACGTATTCACTCCTGATGAGACCCTGGAT
GACTTCACGGACTTTTACCTGGTGATGCCGTTCATGGGCACCGACCTGGGCAAGCTCATG
AAACATGAGAAGCTAGGCGAGGACCGGATCCAGTTCCTCGTGTACCAGATGATGAAGGGG
CTGAGGTATATCCACGCTGCCGGCATCATCCACAGAGACCTGAAGCCCGGCAACCTGGCT
GTGAACGAAGACTGTGAGCTGAAGATCCTGGACTTCGGCCTGGCCAGGCAGGCAGACAGT
GAGATGACTGGGTACGTGGTGACCCGGTGGTACCGGGCTCCCGAGGTCATCTTGAATTGG
ATCGCGTACACGCAGACGGTGGACATCTGGTCTGTGGGCTGCATCATGGCGGAGATGATC
ACAGGCAAGACGCTGTTCAAGGGCAGCGACCACCTGGACCAGCTGAAGGAGATCATGAAG
GTGACGGGGACGCCTCCGGCTGAGTTTGTGCAGCGGCTGCAGAGCGATGAGGCCAAGAAC
TACATGAAGGGCCTCCCCGAATTGGAGAAGAAGGATTTTGCCTCTATCCTGACCAATGCA
AGCCCTCTGGCTGTGAACCTCCTGGAGAAGATGCTGGTGCTGGACGCGGACATCAGGTTG
ACTGCAGGCGAGTTTCTTTCCCATCCCTACTTCGAGTCCCTGCACGACACGGAAGATGAG
CCCCAGGTCCAGAAGTATGATGACTCCTTTGACTACTTTGACCGCACACTGGATGAATGG
AAGCGTGTTACTTACAAAGAGGTGCTCAGCTTCAAGCCTCCCCGGCAGCTGGGGGCCAGG
GTCTCCAAGGAGACGCCTCTGTGA

# Drug_Target_7_General_Function:
Involved in MAP kinase activity

# Drug_Target_7_General_References:
10212242	Hasegawa M, Cuenda A, Spillantini MG, Thomas GM, Buee-Scherrer V, Cohen P, Goedert M: Stress-activated protein kinase-3 interacts with the PDZ domain of alpha1-syntrophin. A mechanism for specific substrate recognition. J Biol Chem. 1999 Apr 30;274(18):12626-31.
10591208	Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE, Bruskiewich R, Beare DM, Clamp M, Smink LJ, Ainscough R, Almeida JP, Babbage A, Bagguley C, Bailey J, Barlow K, Bates KN, Beasley O, Bird CP, Blakey S, Bridgeman AM, Buck D, Burgess J, Burrill WD, O'Brien KP, et al.: The DNA sequence of human chromosome 22. Nature. 1999 Dec 2;402(6761):489-95.
11991731	Court NW, dos Remedios CG, Cordell J, Bogoyevitch MA: Cardiac expression and subcellular localization of the p38 mitogen-activated protein kinase member, stress-activated protein kinase-3 (SAPK3). J Mol Cell Cardiol. 2002 Apr;34(4):413-26.
12167088	Wiltshire C, Matsushita M, Tsukada S, Gillespie DA, May GH: A new c-Jun N-terminal kinase (JNK)-interacting protein, Sab (SH3BP5), associates with mitochondria. Biochem J. 2002 Nov 1;367(Pt 3):577-85.
8633070	Lechner C, Zahalka MA, Giot JF, Moller NP, Ullrich A: ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast differentiation. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4355-9.
8920915	Li Z, Jiang Y, Ulevitch RJ, Han J: The primary structure of p38 gamma: a new member of p38 group of MAP kinases. Biochem Biophys Res Commun. 1996 Nov 12;228(2):334-40.
9169156	Goedert M, Hasegawa J, Craxton M, Leversha MA, Clegg S: Assignment of the human stress-activated protein kinase-3 gene (SAPK3) to chromosome 22q13.3 by fluorescence in situ hybridization. Genomics. 1997 May 1;41(3):501-2.

# Drug_Target_7_HGNC_ID:
HGNC:6874

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
4751

# Drug_Target_7_Locus:
22q13.33

# Drug_Target_7_Molecular_Weight:
41941

# Drug_Target_7_Name:
Mitogen-activated protein kinase 12

# Drug_Target_7_Number_of_Residues:
367

# Drug_Target_7_PDB_ID:
1CM8

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF00069	Pkinase

# Drug_Target_7_Protein_Sequence:
>Mitogen-activated protein kinase 12
MSSPPPARSGFYRQEVTKTAWEVRAVYRDLQPVGSGAYGAVCSAVDGRTGAKVAIKKLYR
PFQSELFAKRAYRELRLLKHMRHENVIGLLDVFTPDETLDDFTDFYLVMPFMGTDLGKLM
KHEKLGEDRIQFLVYQMLKGLRYIHAAGIIHRDLKPGNLAVNEDCELKILDFGLARQADS
EMTGYVVTRWYRAPEVILNWMRYTQTVDIWSVGCIMAEMITGKTLFKGSDHLDQLKEIMK
VTGTPPAEFVQRLQSDEAKNYMKGLPELEKKDFASILTNASPLAVNLLEKMLVLDAEQRV
TAGEALAHPYFESLHDTEDEPQVQKYDDSFDDVDRTLDEWKRVTYKEVLSFKPPRQLGAR
VSKETPL

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
Responds to activation by environmental stress and pro- inflammatory cytokines by phosphorylating downstream targets. Plays a role in myoblast differentiation and also in the down- regulation of cyclin D1 in response to hypoxia in adrenal cells suggesting MAPK12 may inhibit cell proliferation while promoting differentiation

# Drug_Target_7_SwissProt_ID:
P53778

# Drug_Target_7_SwissProt_Name:
MK12_HUMAN

# Drug_Target_7_Synonyms:
EC 2.7.11.24
ERK-6
ERK5
Extracellular signal-regulated kinase 6
MAP kinase p38 gamma
Mitogen-activated protein kinase p38 gamma
Stress-activated protein kinase 3

# Drug_Target_7_Theoretical_pI:
6.33

# Drug_Target_7_Transmembrane_Regions:
None

# Drug_Target_8_Cellular_Location:
Not Available

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
PRKCQ

# Drug_Target_8_GenBank_ID_Gene:
L01087

# Drug_Target_8_GenBank_ID_Protein:
558099

# Drug_Target_8_GeneCard_ID:
PRKCQ

# Drug_Target_8_Gene_Name:
PRKCQ

# Drug_Target_8_Gene_Sequence:
>2121 bp
ATGTCGCCATTTCTTCGGATTGGCTTGTCCAACTTTGACTGCGGGTCCTGCCAGTCTTGT
CAGGGCGAGGCTGTTAACCCTTACTGTGCTGTGCTCGTCAAAGAGTATGTCGAATCAGAG
AACGGGCAGATGTATATCCAGAAAAAGCCTACCATGTACCCACCCTGGGACAGCACTTTT
GATGCCCATATCAACAAGGGAAGAGTCATGCAGATCATTGTGAAAGGCAAAAACGTGGAC
CTCATCTCTGAAACCACCGTGGAGCTCTACTCGCTGGCTGAGAGGTGCAGGAAGAACAAC
GGGAAGACAGAAATATGGTTAGAGCTGAAACCTCAAGGCCGAATGCTAATGAATGCAAGA
TACTTTCTGGAAATGAGTGACACAAAGGACATGAATGAATTTGAGACGGAAGGCTTCTTT
GCTTTGCATCAGCGCCGGGGTGCCATCAAGCAGGCAAAGGTCCACCACGTCAAGTGCCAC
GAGTTCACTGCCACCTTCTTCCCACAGCCCACATTTTGCTCTGTCTGCCACGAGTTTGTC
TGGGGCCTGAACAAACAGGGCTACCAGTGCCGACAATGCAATGCAGCAATTCACAAGAAG
TGTATTGATAAAGTTATAGCAAAGTGCACAGGATCAGCTATCAATAGCCGAGAAACCATG
TTCCACAAGGAGAGATTCAAAATTGACATGCCACACAGATTTAAAGTCTACAATTACAAG
AGCCCGACCTTCTGTGAACACTGTGGGACCCTGCTGTGGGGACTGGCACGGCAAGGACTC
AAGTGTGATGCATGTGGCATGAATGTGCATCATAGATGCCAGACAAAGGTGGCCAACCTT
TGTGGCATAAACCAGAAGCTAATGGCTGAAGCGCTGGCCATGATTGAGAGCACTCAACAG
GCTCGCTGCTTAAGAGATACTGAACAGATCTTCAGAGAAGGTCCGGTTGAAATTGGTCTC
CCATGCTCCATCAAAAATGAAGCAAGGCTGCCATGTTTACCGACACCGGGAAAAAGAGAG
CCTCAGGGCATTTCCTGGGAGTCTCCGTTGGATGAGGTGGATAAAATGTGCCATCTTCCA
GAACCTGAACTGAACAAAGAAAGACCATCTCTGCAGATTAAACTAAAAATTGAGGATTTT
ATCTTGCACAAAATGTTGGGGAAAGGAAGTTTTGGCAAGGTCTTCCTGGCAGAATTCAAG
AAAACCAATCAATTTTTCGCAATAAAGGCCTTAAAGAAAGATGTGGTCTTGATGGACGAT
GATGTTGAGTGCACGATGGTAGAGAAGAGAGTTCTTTCCTTGGCCTGGGAGCATCCGTTT
CTGACGCACATGTTTTGTACATTTCAGACCAAGGAAAACCTCTTTTTTGTGATGGAGTAC
CTCAACGGAGGGGACTTAATGTACCACATCCAAAGCTGCCACAAGTTCGACCTTTCCAGA
GCGACGTTTTATGCTGCTGAAATCATTCTTGGTCTGCAGTTCCTTCATTCCAAAGGAATA
GTCTACAGGGACCTGAAGCTAGATAACATCCTGTTAGACAAAGATGGACATATCAAGATC
GCGGATTTTGGAATGTGCAAGGAGAACATGTTAGGAGATGCCAAGACGAATACCTTCTGT
GGGACACCTGACTACATCGCCCCAGAGATCTTGCTGGGTCAGAAATACAACCACTCTGTG
GACTGGTGGTCCTTCGGGGTTCTCCTTTATGAAATGCTGATTGGTCAGTCGCCTTTCCAC
GGGCAGGATGAGGAGGAGCTCTTCCACTCCATCCGCATGGACAATCCCTTTTACCCACGG
TGGCTGGAGAAGGAAGCAAAGGACCTTCTGGTGAAGCTCTTCGTGCGAGAACCTGAGAAG
AGGCTGGGCGTGAGGGGAGACATCCGCCAGCACCCTTTGTTTCGGGAGATCAACTGGGAG
GAACTTGAACGGAAGGAGATTGACCCACCGTTCCGGCCGAAAGTGAAATCACCATTTGAC
TGCAGCAATTTCGACAAAGAATTCTTAAACGAGAAGCCCCGGCTGTCATTTGCCGACAGA
GCACTGATCAACAGCATGGACCAGAATATGTTCAGGAACTTTTCCTTCATGAACCCCCGG
ATGGAGCGGCTGATATCCTGA

# Drug_Target_8_General_Function:
Involved in protein serine/threonine kinase activity

# Drug_Target_8_General_References:
10636891	Witte S, Villalba M, Bi K, Liu Y, Isakov N, Altman A: Inhibition of the c-Jun N-terminal kinase/AP-1 and NF-kappaB pathways by PICOT, a novel protein kinase C-interacting protein with a thioredoxin homology domain. J Biol Chem. 2000 Jan 21;275(3):1902-9.
7686153	Chang JD, Xu Y, Raychowdhury MK, Ware JA: Molecular cloning and expression of a cDNA encoding a novel isoenzyme of protein kinase C (nPKC). A new member of the nPKC family expressed in skeletal muscle, megakaryoblastic cells, and platelets. J Biol Chem. 1993 Jul 5;268(19):14208-14.
8444877	Baier G, Telford D, Giampa L, Coggeshall KM, Baier-Bitterlich G, Isakov N, Altman A: Molecular cloning and characterization of PKC theta, a novel member of the protein kinase C (PKC) gene family expressed predominantly in hematopoietic cells. J Biol Chem. 1993 Mar 5;268(7):4997-5004.

# Drug_Target_8_HGNC_ID:
HGNC:9410

# Drug_Target_8_HPRD_ID:
02710

# Drug_Target_8_ID:
2530

# Drug_Target_8_Locus:
10p15

# Drug_Target_8_Molecular_Weight:
81866

# Drug_Target_8_Name:
Protein kinase C theta type

# Drug_Target_8_Number_of_Residues:
706

# Drug_Target_8_PDB_ID:
1XJD

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF00069	Pkinase
PF00130	C1_1
PF00433	Pkinase_C

# Drug_Target_8_Protein_Sequence:
>Protein kinase C theta type
MSPFLRIGLSNFDCGSCQSCQGEAVNPYCAVLVKEYVESENGQMYIQKKPTMYPPWDSTF
DAHINKGRVMQIIVKGKNVDLISETTVELYSLAERCRKNNGKTEIWLELKPQGRMLMNAR
YFLEMSDTKDMNEFETEGFFALHQRRGAIKQAKVHHVKCHEFTATFFPQPTFCSVCHEFV
WGLNKQGYQCRQCNAAIHKKCIDKVIAKCTGSAINSRETMFHKERFKIDMPHRFKVYNYK
SPTFCEHCGTLLWGLARQGLKCDACGMNVHHRCQTKVANLCGINQKLMAEALAMIESTQQ
ARCLRDTEQIFREGPVEIGLPCSIKNEARPPCLPTPGKREPQGISWESPLDEVDKMCHLP
EPELNKERPSLQIKLKIEDFILHKMLGKGSFGKVFLAEFKKTNQFFAIKALKKDVVLMDD
DVECTMVEKRVLSLAWEHPFLTHMFCTFQTKENLFFVMEYLNGGDLMYHIQSCHKFDLSR
ATFYAAEIILGLQFLHSKGIVYRDLKLDNILLDKDGHIKIADFGMCKENMLGDAKTNTFC
GTPDYIAPEILLGQKYNHSVDWWSFGVLLYEMLIGQSPFHGQDEEELFHSIRMDNPFYPR
WLEKEAKDLLVKLFVREPEKRLGVRGDIRQHPLFREINWEELERKEIDPPFRPKVKSPFD
CSNFDKEFLNEKPRLSFADRALINSMDQNMFRNFSFMNPGMERLIS

# Drug_Target_8_Reaction:
ATP + a protein = ADP + a phosphoprotein

# Drug_Target_8_Signals:
None

# Drug_Target_8_Specific_Function:
PKC is activated by diacylglycerol which in turn phosphorylates a range of cellular proteins. PKC also serves as the receptor for phorbol esters, a class of tumor promoters

# Drug_Target_8_SwissProt_ID:
Q04759

# Drug_Target_8_SwissProt_Name:
KPCT_HUMAN

# Drug_Target_8_Synonyms:
EC 2.7.11.13
nPKC-theta

# Drug_Target_8_Theoretical_pI:
7.64

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Centrosome. Spindle. Note=Localizes on centrosomes in interphase cells and at each spindle pole in m

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
AURKA

# Drug_Target_9_GenBank_ID_Gene:
D84212

# Drug_Target_9_GenBank_ID_Protein:
2641948

# Drug_Target_9_GeneCard_ID:
AURKA

# Drug_Target_9_Gene_Name:
AURKA

# Drug_Target_9_Gene_Sequence:
>1209 bp
ATGGACCGATCTAAAGAAAACTGCATTTCAGGACCTGTTAAGGCTACAGCTCCAGTTGGA
GGTCCAAAACGTGTTCTCGTGACTCAGCAATTTCCTTGTCAGAATCCATTACCTGTAAAT
AGTGGCCAGGCTCAGCGGGTCTTGTGTCCTTCAAATTCTTCCCAGCGCGTTCCTTTGCAA
GCACAAAAGCTTGTCTCCAGTCACAAGCCGGTTCAGAATCAGAAGCAGAAGCAATTGCAG
GCAACCAGTGTACCTCATCCTGTCTCCAGGCCACTGAATAACACCCAAAAGAGCAAGCAG
CCCCTGCCATCGCACCTGAAAATAATCCTGAGGAGGAACTGGCATCAAAACAGAAAAATG
AAGAATCAAAAAGAGGCAGTGGCTTTGGAAGACTTTGAAATTGGTCGCCCTCTGGGTAAA
GGAAAGTTTGGTAATGTTTATTTGGCAAGAGAAAAGCAAAGCAAGTTTATTCTGGCTCTT
AAAGTGTTATTTAAAGCTCAGCTGGAGAAAGCCGGAGTGGAGCATCAGCTCAGAAGAGAA
GTAGAAATACAGTCCCACCTTCGGCATCCTAATATTCTTAGACTGTATGGTTATTTCCAT
GATGCTACCAGAGTCTACCTAATTCTGGAATATGCACCACTTGGAACAGTTTATAGAGAA
CTTCAGAAACTTTCAAAGTTTGATGAGCAGAGAACTGCTAACTTATATAACAGAATTGCA
AATGCCCTGTCTTACTGTCATTCGAAGAGAGTTATTCATAGAGACATTAAGCCAGAGAAC
TTACTTCTTGGATCAGCTGGAGAGCTTAAAATTGCAGATTTTGGGTGGTCAGTACATGCT
CCATCTTCCAGGAGGACCACTCTCTGTGGCACCCTGGACTACCTGCCCCCTGAAATGATT
GAAGGTCGGATGCATGATGAGAAGGTGGATCTCTGGAGCCTTGGAGTTCTTTGCTATGAA
TTTTTAGTTGGGAAGCCTCCTTTTGAGGCAAACACATACCAAGAGACCTACAAAAGAATA
TCACGGGTTGAATTCACATTCCCTGACTTTGTAACAGAGGGAGCCAGGGACCTCATTTCA
AGACTGTTGAAGCATAATCCCAGCCAGAGGCCAATGCTCAGAGAAGTACTTGAACACCCC
TGGATCACAGCAAATTCATCAAAACCATCAAATTGCCAAAACAAAGAATCAGCTAGCAAA
CAGTCTTAG

# Drug_Target_9_General_Function:
Involved in protein kinase activity

# Drug_Target_9_General_References:
11413462	Nigg EA: Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol. 2001 Jan;2(1):21-32.
11780052	Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J: The DNA sequence and comparative analysis of human chromosome 20. Nature. 2001 Dec 20-27;414(6866):865-71.
11790771	Tanaka M, Ueda A, Kanamori H, Ideguchi H, Yang J, Kitajima S, Ishigatsubo Y: Cell-cycle-dependent regulation of human aurora A transcription is mediated by periodic repression of E4TF1. J Biol Chem. 2002 Mar 22;277(12):10719-26. Epub 2002 Jan 14.
12467573	Nowakowski J, Cronin CN, McRee DE, Knuth MW, Nelson CG, Pavletich NP, Rogers J, Sang BC, Scheibe DN, Swanson RV, Thompson DA: Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography. Structure. 2002 Dec;10(12):1659-67.
9153231	Kimura M, Kotani S, Hattori T, Sumi N, Yoshioka T, Todokoro K, Okano Y: Cell cycle-dependent expression and spindle pole localization of a novel human protein kinase, Aik, related to Aurora of Drosophila and yeast Ipl1. J Biol Chem. 1997 May 23;272(21):13766-71.
9514916	Shindo M, Nakano H, Kuroyanagi H, Shirasawa T, Mihara M, Gilbert DJ, Jenkins NA, Copeland NG, Yagita H, Okumura K: cDNA cloning, expression, subcellular localization, and chromosomal assignment of mammalian aurora homologues, aurora-related kinase (ARK) 1 and 2. Biochem Biophys Res Commun. 1998 Mar 6;244(1):285-92.
9771714	Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR, Sen S: Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet. 1998 Oct;20(2):189-93.

# Drug_Target_9_HGNC_ID:
HGNC:11393

# Drug_Target_9_HPRD_ID:
04066

# Drug_Target_9_ID:
1422

# Drug_Target_9_Locus:
20q13.2-q13.3

# Drug_Target_9_Molecular_Weight:
45810

# Drug_Target_9_Name:
Serine/threonine-protein kinase 6

# Drug_Target_9_Number_of_Residues:
403

# Drug_Target_9_PDB_ID:
2BMC

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF00069	Pkinase

# Drug_Target_9_Protein_Sequence:
>Serine/threonine-protein kinase 6
MDRSKENCISGPVKATAPVGGPKRVLVTQQFPCQNPLPVNSGQAQRVLCPSNSSQRVPLQ
AQKLVSSHKPVQNQKQKQLQATSVPHPVSRPLNNTQKSKQPLPSAPENNPEEELASKQKN
EESKKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRR
EVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITEL
ANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLCGTLDYLPPEM
IEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLI
SRLLKHNPSQRPMLREVLEHPWITANSSKPSNCQNKESASKQS

# Drug_Target_9_Reaction:
ATP + a protein = ADP + a phosphoprotein

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
May play a role in cell cycle regulation during anaphase and/or telophase, in relation to the function of the centrosome/spindle pole region during chromosome segregation. Maybe involved in microtubule formation and/or stabilization. May play a key role during tumor development and progression

# Drug_Target_9_SwissProt_ID:
O14965

# Drug_Target_9_SwissProt_Name:
STK6_HUMAN

# Drug_Target_9_Synonyms:
Aurora kinase A
Aurora-A
Aurora-related kinase 1
Aurora/IPL1-related kinase 1
Breast-tumor-amplified kinase
EC 2.7.11.1
Serine/threonine kinase 15
hARK1

# Drug_Target_9_Theoretical_pI:
9.90

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB02482
